Virax Biolabs Group Limited (NasdaqCM: VRAX)
Health Care · Health Care Providers & Services · GB
$2.91
+1.75% today · -85.4% 1Y
Virax Biolabs Group Limited (NasdaqCM: VRAX) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $2.28M and employs 26 people.
Over the last twelve months the share price has lost 85.4%, trading between 2.50 and 21.75.
Tweenvest scores Virax Biolabs Group Limited across four factors: quality 27/100, value 43/100. Its strongest factor is value.
VRAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.28M
- Revenue (TTM)
- $12.42K
- P/E
- —
- EPS
- -12.64
- Dividend yield
- —
- Beta (5Y)
- 1.34
- 52-week high
- $21.75
- 52-week low
- $2.50
- Avg volume (3M)
- —
- Shares outstanding
- 796.99K
- Employees
- 26
- Next earnings
- —
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
- ISIN
- KYG9495L1335
- Founded
- 2013
- Listed since
- Jul 21, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| UnitedHealth Group IncorporatedNYSE: UNH | $355.98B | $396.59 | -0.54% |
| CVS Health CorporationNYSE: CVS | $118.82B | $92.90 | -1.29% |
| McKesson CorporationNYSE: MCK | $105.52B | $905.09 | +3.58% |
| HCA Healthcare, Inc.NYSE: HCA | $92.83B | $428.76 | -0.11% |
| Elevance Health, Inc.NYSE: ELV | $86.50B | $398.87 | -0.93% |
| The Cigna GroupNYSE: CI | $73.81B | $279.32 | -0.40% |
| Cencora, Inc.NYSE: COR | $62.60B | $328.06 | +1.33% |
| Cardinal Health, Inc.NYSE: CAH | $55.33B | $237.92 | +2.39% |
Figures last refreshed Aug 18, 2026.